科瑞技術(002957.SZ):擬使用不超2.5億元自有閒置資金用於風險投資
格隆匯 11 月 24日丨科瑞技術(002957.SZ)公佈,公司於2020年11月24日召開第三屆董事會第十一次會議,審議通過了《關於使用自有閒置資金進行風險投資的議案》,同意公司及子公司在充分保障日常運營性資金需求、不影響公司及子公司正常生產經營並有效控制風險的前提下,使用自有閒置資金用於風險投資,投資最高額度不超過2.5億元人民幣,使用期限自公司董事會審議通過之日起一年內有效,該額度在使用期限內可以循環滾動使用。
根據《深圳證券交易所上市公司規範運作指引》等相關法律法規和規範性文件的規定,本次使用自有閒置資金進行風險投資屬於董事會審批權限範圍,無需提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.